EnvoyerImprimer

Governance

Presentation of the cluster

Governance

Lyonbiopôle governance: a collective, complementary international-scale process, managed by a versatile team

 

As a result of the cluster building process, the Lyonbiopôle association brings together players, directly or potentially involved in R&D projects, that make the region’s firms and stakeholders even stronger.


The Lyonbiopôle association was created on November 8, 2005 during the founding general assembly, at which the members of the Board of Directors and Technical Group were named. These two bodies feature representatives from major groups, SMBs, start-ups, training centers and research centers or laboratories that are founding members of the association.

 

The Board of Directors

Lyonbiopôle’s Board is headed by Philippe Archinard, Managing Director of Transgene and Scientific Director of Mérieux Alliance. He was named as the successor to Docteur Christophe Mérieux on October 5, 2006.

 

The Board is composed of 12 members:
  • 6 firms represented by their managers :
    • bioMérieux - Alain Mérieux , Président
    • sanofi pasteur - Jacques Berger, Deputy Managing Director
    • Merial SAS - Jean-Louis Crosia, President
    • Becton Dickinson France SAS- Christian Seux, President
    • Transgene - Philippe Archinard, Directeur Général
    • BioMérieux - Peter Kaspar,  R&D Director
    • PX'Therapeutics - Tristan Rousselle, Chief Executive Officer
    • Alizé Pharma - Thierry Abribat, co-Founder & President

 

 

 

Local authorities are "permanent guests" on the Board:

  • Greater Lyon - Gilles Rabin, Deputy Managing Director
  • Région Rhône-Alpes - Rachel Haab, DERTT Director
  • Grenoble Alpes Métropole – Pierre Tonneau, Deputy Managing Director
  • DRIRE Rhône Alpes -  Hubert Virlet, Adjoint au chef de la division développement industriel

 

The Technical Group

The Board of Directors created a Technical Group whose roles include:

  • 1. Tracking and reporting on Lyonbiopôle’s activities, in particular R&D projects and multi-disciplinary and joint actions.
  • 2. Analyzing R&D projects and proposing that the Board grant them the cluster label, while ensuring that the projects are consistent with Lyonbiopôle’s strategy.
  • 3. 3. Proposing strategies in order to bring in additional funding for Lyonbiopôle’s projects and joint actions.

 

The Technical Group has 8 members:

 

 

GD€co: working group (Development Economic Group )

Mission:

  • reflect on the actions and instruments for SME development
  • make recommendations which, after approval by the Board of LyonBiopôle, will be implemented in the form of shares
  • Composition: 10 companies have joined the GD€co 

          o PX'Therapeutics-Tristan Rousselle, CEO
          o Alizé Pharma SAS - Thierry Abribat, President

          o Transgene - François Valencony Director, Corporate Development
          o Bio ALTRA - Laurent BUFFAT, CEO
          o Genoway - Fraichard Alexander, CEO
          o Imaxio - François MICELI, CEO
          o OSEO Anvar - Thomas Delale Chargé d'affaires

          o Edelris - Jean-Yves ORTHOLAND, CEO
          o ERYTHECH PHARMA - Pierre-Olivier Goineau, CEO
          o Octalfa - Gilles Alberici,Chairman


 

Lyonbiopôle’s management team
The Board of Directors and Technical Group are supported by a small, flexible management team entrusted with 4 missions:

  1. Initiating and supporting the set-up of multi-partner R&D projects and following up on them throughout their deployment
  2. Bringing in human and financial resources for the cluster’s projects
  3. Coordinating special events and communication between the firms and technical institutes
  4. Handling the promotion of Lyonbiopôle, its member firms and institutes and its R&D projects

The team includes 12 permanent members: